Search 

uniQure is a world-leading gene therapy company. Our lead product, Glybera, received a positive opinion from CHMP in July 2012 and is poised to become the first gene therapy approved in the Western World, capping more than 30 years research in this area.

This positive outcome validates uniQure's AAV platform and, most importantly, the only commercially scalable manufacturing system currently available anywhere.

uniQure's plug-and-play platform offers the opportunity to develop many additional therapies on a platform that is now validated and accepted as safe by regulatory authorities.

uniQure's second programme, for Hemophilia B ($1.5bn market) is in a Phase I/II clinical study and has shown up to 30 months stable, therapeutic expression from a single treatment (NEJM Dec 2011).

Over the coming 6 months further programmes for Porphyria, Parkinson's Disease and Sanfilippo B are expected to enter Phase I/II clinical trials.

uniQure is based in Amsterdam, and backed by Forbion, Gilde, Advent, CAPE and other investors. We would be interested in meeting to discuss potential collaborations and also potential investment opportunities.

Virometix is a privately held young innovative Swiss Biotech company developing a new class of vaccines, which should overcome limitations of current biological vaccines in terms of safety, efficacy, speed, stability and manufacturing cost. Virometix Synthetic Virus-Like Nanoparticle (SVLP) technology platform offers the following value propositions:

Safety. Virometix SVLP-based vaccines avoid the use of life pathogens and the safety concerns associated with the biological manufacturing processes used for conventional vaccines.

Quality. SVLPs are based on a proprietary lipopeptide self-assembly process that leads to atomically defined nanoparticles with a constant size and number of lipopeptide monomers per particle, which increases the specificity and quality of the elicited immune response and assures lot-to-lot consistency.

Efficacy. SVLPs efficiently deliver antigens to antigen presenting cells for optimal B- and T-cell responses and induce antibodies that bind with very high affinity to the native target antigen.

Convenience. SVLPs do not require sonication, refolding, extrusion or similar processes. SVLPs can be prepared by simply dissolving freeze-dried lipopeptide monomers in a buffer suitable for injection shortly before use.

The protective potential of Virometix nanoparticles has been demonstrated for various targets in in vitro and in vivo. Virometix currently develops vaccines for infectious diseases and cancer and offers collaborative research and licensing partnerships for selected vaccines in these areas, and licensing opportunities for selected areas outside Virometix core focus.